The Outsourcing Facilities Association is appealing a ruling that rejected their request for an injunction against the FDA’s ...

BofA analyst Allen Lutz notes that the Food and Drug Administration yesterday provided updated enforcement timelines for semaglutide and ...

The health regulator announced last month that there was no longer a shortage of Novo's Wegovy and diabetes drug Ozempic, ...

In today’s evolving pharmaceutical environment, the fill‐finish segment stands out as a critical linchpin connecting drug ...

A federal judge has shut down compounding pharmacies from making cheaper versions of Eli Lilly’s weight loss and diabetes ...

A federal judge ended compounding pharmacies’ ability to make copies of the weight loss and diabetes drugs Zepbound and ...

On February 21, 2025, the US Food and Drug Administration (FDA) revised its shortage categorization of semaglutide, a glucagon-like peptide 1 ...

The Outsourcing Facilities Association (OFA) alleged the agency was “abruptly depriving patients of much needed treatment and ...

Compounders had been allowed to produce and sell hundreds of thousands of their own versions of popular anti-obesity drugs.

A U.S. federal judge has restricted compounding pharmacies from making copies of Eli Lilly's weight-loss and diabetes drugs due to a lawsuit against the FDA's decision that there's no longer a ...

The last few years have seen several major disruptions that have impacted businesses and operations. Events like the COVID-19 ...